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We recently reported an interesting finding that the Ebola virus (EBOV) encodes functional microRNAs 
(miRNAs) that can be produced through the host’s miRNA processing machinery. Furthermore, prediction of 
EBOV miRNA target genes provided some clues about the regulatory roles of EBOV miRNAs. In summary, our 
study paves the road for further investigating the roles of EBOV miRNAs in viral infection and virus-host 
interactions. 
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Ebola virus (EBOV) is a type of filovirus with an 
enveloped negative-sense RNA genome. EBOV usually 
causes severe and lethal infections in humans and primates 
[1]. The Ebola virus disease (EVD) has a high risk of death, 
killing 50%-90% of infected patients [1]. Recently, the 
outbreak of EVD in West Africa brought international 
attention to the virus [2]. As of December 14th 2014, there 
have been 18,603 reported EBOV cases in eight countries 
since the beginning of the outbreak, with 6,915 reported 
deaths according to the WHO. Currently, no effective 
treatment or diagnostic method for EVD is available [3], and 
the detailed molecular mechanisms underlying EBOV 
infection, immune evasion, pathogenesis, and host 
interaction are far from clear.  
microRNAs (miRNAs) are a class of small non-coding 
RNAs that play pivotal roles in a variety of physiological 
processes [4, 5]. miRNAs are not only found in eukaryotes but 
are also transcribed by various viruses to manipulate their 
own genes and/or the hosts’ genes [6, 7], and they are believed 
to be important regulators of the virus-host interaction and 
key elements in viral pathogenesis [8]. At present, most of the 
known viral miRNAs have been identified to be encoded by 
DNA viruses, because DNA viruses replicate in the nucleus 
and thus can hijack the host’s miRNA processing machinery. 
In contrast, RNA viruses replicate in the cytoplasm and have 
no access to the host’s miRNA processing machinery [9]. 
Therefore, the capacity of RNA viruses to encode miRNAs 
has previously been neglected. 
Despite these preconceived notions, recent studies have 
confirmed that laboratory-engineered RNA viruses (e.g., 
Sindbis virus, vesicular stomatitis virus, and influenza virus) 
are able to express miRNA-like small RNAs [10-14]. In 
addition, several retroviruses (e.g., human immunodeficiency 
virus, bovine leukemia virus, and several cytoplasmic RNA 
viruses), were found to encode miRNAs, although the 
underlying mechanisms remain unclear. It was further 
confirmed that the EBOV VP35 protein had the ability to 
suppress RNA silencing, which provides a clue about the link 
between EBOV and miRNAs [15, 16]. Furthermore, it was 
reported that the expression of three endogenous miRNAs 
was increased in human umbilical vein endothelial cells upon 
infection with EBOV GP-expressing adenovirus [17]. This 
study not only provides important evidence for 
understanding the human-EBOV interaction but also offers 
some clues about the indispensable contribution of miRNA 
to the virulence of EBOV.  
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In our recent study, we hypothesized that the genome of 
EBOV could produce miRNAs using the host’s miRNA 
processing system [18]. To investigate this possibility, we 
used a strategy that combined bioinformatic analysis and 
experimental validation to search for putative EBOV 
miRNAs. We identified two putative viral miRNA precursors 
and three putative mature miRNAs derived from the EBOV 
genome. The miRNAs were found to be Dicer-dependent and 
functionally active in vitro. The results of a cellular target 
prediction analysis indicated that EBOV miRNAs could 
regulate various host genes involved in virus-host interaction, 
immune escape, and cell apoptosis [18], which may explain 
how EBOV can duplicate massively without being detected 
by the host immune system and cause severe hemorrhagic 
fever symptoms. Interestingly, we found that the Reston 
EBOV strain did not encode these miRNAs, in contrast to the 
Sudan and Zaire EBOV strains, which have high 
pathogenicity and mortality rates in humans. This may 
explain, at least in part, the non-pathogenicity of Reston 
EBOV to humans. 
Taken together, our study provides evidence to support the 
hypothesis that EBOV, as an RNA virus, is capable of 
encoding functional miRNAs via the host’s miRNA 
processing machinery. Our findings pave the road for further 
investigating the roles of the EBOV miRNAs during viral 
infection and virus-host interactions. Furthermore, our 
findings may have some clinical applications. The detection 
of circulating EBOV miRNAs in human blood may provide 
an effective tool for the diagnosis of EBOV infection, 
considering that specific miRNAs encoded by infectious 
virus have been detected in human blood samples and can 
serve as sensitive and specific indicators for virus infection. 
The advantage of EBOV miRNAs as non-invasive 
biomarkers guarantees the accuracy and promptness of the 
detection of disease, which can enable fast isolation and early 
treatment, prevent the spread of the virus, and increase the 
survival opportunity of the patients. As for the treatment of 
EBOV disease, miRNA may also be a promising target. 
Specific treatments targeting EBOV miRNAs may impede 
the virus’ immune evasion, reactivate immune surveillance 
and induce pathogen elimination. Future work will evaluate 
the sensitivity, specificity, and accuracy of this approach by 
assessing EBOV miRNAs in blood samples from 
EBOV-infected patients. Future studies should also be 
focused on investigating the targets and pathogenic 
mechanisms of EBOV miRNAs. We believe that the 
investigation of miRNAs may provide a turning point that 
allows us to uncover the mechanisms of EBOV pathogenesis 
and immune evasion and elucidate the intricate relationship 
between the virus and human beings. 
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